A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

References

Page 1

	Year	Citations
Cancer statistics, 2018 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal CA A Cancer Journal for Clinicians	2018	16.8K
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer Philip Cornford, Joaquim Bellmunt, M. Bolla, European Urology Surgical OncologyUrologyGenitourinary CancerMedicineCancer Management	2016	1.4K
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer Maha Hussain, Catherine M. Tangen, Donna L. Berry, New England Journal of Medicine	2013	562
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy Juanita Crook, Christopher J. O’Callaghan, Graeme Duncan, New England Journal of Medicine	2012	489
Gonadotropin-Releasing Hormone and Its Analogues New England Journal of Medicine InfertilityUrologyHormonal ContraceptiveFertilityEndocrine Mechanism	1991	464
Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer Jerome Seidenfeld, Vic Hasselblad, Naomi Aronson, Annals of Internal Medicine	2000	395
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. G. Tolis, DCF ACKMAN, A. Stellos, Proceedings of the National Academy of Sciences UrologyGrowth HormoneHuman GrowthMedicineStage C	1982	368
Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10 Takumi Fukuda, Susumu Shinagawa, Shigeru Kobayashi, Biochemical and Biophysical Research Communications Position 6Growth HormoneSynthetic AnalogsBiochemistryEndocrine Mechanism	1974	130
A 12-Month Clinical Study of LA-2585 (45.0 MG): A New 6-Month Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer E. David Crawford, Oliver Sartor, Franklin Chu, The Journal of Urology	2006	98
Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group Fernando Calais da Silva, F.M. Calais da Silva European Urology Surgical OncologyUrologyMaximal Androgen BlockadeGenitourinary CancerMedicine	2013	74

Page 1